Onco Wiki / Indication

Post-Transplant Lymphoproliferative Disorder · Rituximab + CHOP (R-CHOP), 6 cycles

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Trackaggressive
Linked regimenREG-R-CHOP
IDIND-PTLD-1L-RCHOP
TypeIndication
Statusreviewed 2026-04-25 | pending_clinical_signoff
DiseasesDIS-PTLD
SourcesSRC-NCCN-BCELL-2025

Notes

STUB. Step 3 of 4-step PTLD ladder. CD19 CAR-T для refractory — ще не модельовано як окрема Indication.

Used By

Algorithms

Indication